Merck/Schering-Plough Initiate Vytorin Acute Coronary Syndrome Trial
This article was originally published in The Pink Sheet Daily
The two-year, 10,000-patient IMPROVE IT study will evaluate the Zetia/Zocor combination's morbidity/mortality risk reduction compared to Zocor alone. The trial will compare Vytorin 10 mg/40 mg to Zocor 40 mg in patients with acute coronary syndrome.
You may also be interested in...
Merck/Schering’s fixed-dose combination is ahead of AstraZeneca’s Crestor at a similar time during its launch, Schering-Plough says. Schering is also pleased with Vytorin’s level of managed care access.
The Irvine, Calif., firm also plans sNDAs for a colorectal cancer claim and an oral formulation of the leucovorin relative.
Encysive may be forced to make "significant reductions" to infrastructure and workforce, firm says June 15.